Index of drugs

Reduction of elevated intraocular pressure in patients with open-angle glaucoma and intraocular hypertension. The indication for the use of the drug in children and adolescents is increased intraocular pressure and glaucoma of childhood.

1 ml of solution contains 50 μg latanoprost. The solution contains benzalkonium chloride.

Prostaglandin analog F_2α, a selective prostanoid agonist of FP receptors. It reduces intraocular pressure by increasing the outflow of aqueous humor. Increases choroidal-scleral outflow and reduces the flow resistance. The drug has no significant effect on the production of aqueous humor, does not affect the blood-liquid barrier. The reduction in intraocular pressure occurs about 3-4 hours after application, the maximum effectiveness is achieved after 8-12 h, the effect persists for at least 24 h. Latanoprost is an inactive prodrug that is well absorbed through the cornea, the whole active substance, which enters the aqueous humor is hydrolysed during the transition through the cornea to the biologically active latanoprost acid. The maximum concentration of the drug in aqueous humor occurs approximately 2 hours after administration. It is distributed mainly in the anterior chamber, in the conjunctiva and the eyelids, only minimal amounts reach the chamber of the posterior eye. The drug is practically not metabolized in the eye. Metabolism occurs mainly in the liver. T_0,5 drug in serum is 17 min. Inactive metabolites are mainly excreted in the urine.

Hypersensitivity to latanoprost or to any of the excipients.

Caution should be used in patients with closed-angle, open-angle glaucoma in patients with pseudophakia, pigmented glaucoma, inflammatory glaucoma, neovascular glaucoma, inflammation of the eye, congenital glaucoma or with acute attack of closed-angle glaucoma - limited clinical experience. Caution should be exercised in perioperative patients after cataract extraction and in patients with aphasia, pseudophakia with discontinuous posterior capsule or lenses implanted into the anterior chamber of the eye or patients at risk for cystic macular edema (e.g., diabetic retinopathy and closure of light) retinal vessels). Carefully used in patients with a tendency to develop iritis and / or uveitis. Caution should be used in patients with unstable or severe asthma. During treatment, the pigmentation of the iris may change; treatment can be continued, however, patients should be tested regularly and if required by clinical status, latanoprost should be discontinued. Data on the efficacy and safety of the preparation in children below 1 year of age (4 patients) are very limited. There are no data on the use of the product in newborn infants (before 36 weeks of pregnancy). In children from 0 to 3 years with primary congenital glaucoma, surgical treatment (eg trabeculotomy, goniotomy) remains the primary treatment. The safety profile of long-term use in children has not been established. The preparation contains benzalkonium chloride, which may cause punctate keratopathy and / or toxic ulcerative keratopathy - patients with dry eye syndrome should be carefully monitored or patients with corneal disorders that use the medicine frequently or for a long time. Before administering eye drops, contact lenses should be removed; you can set them up after 15 minutes.

The preparation should not be used during pregnancy. Latanoprost and its metabolites can penetrate into breast milk. Do not use in breast-feeding women or stop breast-feeding.

Very common: increased iris pigmentation (most often in people with mixed iris color, for example: blue-brown, gray-brown, yellow-brown and green-brown) - in some patients the change may be permanent, eye irritation (including the feeling of body presence foreign), changes in the appearance of eyelashes (lengthening, thickening, darkening and increasing the amount). Common: mild to moderate conjunctival hyperemia, transient punctate epithelial defects (most often without symptoms), eyelid inflammation, eye pain. Uncommon: eyelid edema, rash.Rare: Iritis or uveitis, macular edema, symptomatic corneal edema and lesions, periorbital edema, dark eyelid skin, local skin reactions on the eyelids, changes in the direction of eyelash growth (this may cause eye irritation), increase in number, darkening, thickening and elongation of eyelid hair on the eyelid (observed in most cases in the Japanese population), the appearance of a double row of eyelashes on the holes of the thyroid glands, palpitations, asthma, exacerbation of asthma, shortness of breath, pain and dizziness, muscle and joint pain. Very rare: intensification of existing angina pectoris; pain in the chest. There was a change in the color of the skin in the orbital area, in most cases in people of Japanese origin. In children and adolescents, nasopharyngitis and fever were more frequently observed compared to adults.

Adults: 1 drop to the affected eye (eyes) once a day, preferably in the evening. Do not administer the preparation more than once a day. If you miss one dose, continue with the Next scheduled dose. Immediately after instillation, it is recommended to compress the conjunctival sac in the medial part of the eyelid angle for one minute. If the patient uses more than one eye medicine, each of these medicines should be given at least 5 minutes apart. Children and adolescents: the same dosing regimen can be used as for adults. There are no data on the use of the preparation in newborns born before 36 weeks of pregnancy. Data on the use of the product in children <1 year are very limited.